人工神经网络模型预测转移性结直肠癌一线FOLFOX化疗疗效的构建
模型在训练集和测试集的预测准确度分别为75.7%和76.5%,ROC曲线下面积0.875。外部验证集GSE69657(敏感组13例、耐药组17例)的ROC曲线下面积为0.778,提示模型稳定性好、预测效能强。
要点
- 基于39个基因构建的人工神经网络模型可预测mCRC一线FOLFOX疗效
- 训练集与测试集准确度分别为75.7%和76.5%,外部验证AUC为0.778
- 奥沙利铂耐药相关基因功能主要富集于物质代谢调控过程
核心结论
- 基于芯片数据成功建立人工神经网络预测模型,模型稳定性好,预测FOLFOX方案一线治疗mCRC疗效的效能强。
- 与奥沙利铂耐药相关的基因功能主要富集在物质代谢的调控过程中。
研究设计与样本
- 从GEO数据库获取GSE104645作为训练集,含FOLFOX方案一线治疗mCRC敏感组31例和耐药组23例,按7∶3分为内部训练样本和内部测试样本。
- 以福建医科大学附属协和医院结直肠外科30例mCRC患者芯片数据集GSE69657作为外部验证样本,其中敏感组13例、耐药组17例。
- 运用R 3.5.1软件Combat包对两套矩阵表达值进行批间差校正,采用多层感知器方法构建人工神经网络模型,以ROC曲线评价预测能力。
主要发现
- GO分析显示差异基因主要富集在物质代谢的调控过程中。
- 所构建的人工神经网络模型共纳入39个基因,包含2个隐藏层。
- 模型在训练集中预测训练样本和测试样本的准确度分别为75.7%和76.5%,ROC曲线下面积为0.875。
- 外部验证样本的ROC曲线下面积为0.778。
关键数值与推荐
- 以P<0.05且|log(2)FC|>0.33为阈值筛选FOLFOX方案的耐药基因和敏感基因。
- 疗效分组:敏感组包括完全缓解和部分缓解患者,耐药组包括疾病稳定和疾病进展患者。
临床怎么用
- 该模型可用于预测mCRC患者接受一线FOLFOX化疗的疗效,辅助临床决策。
- 物质代谢调控相关基因功能与奥沙利铂耐药相关,可为耐药机制研究提供线索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore and establish an artificial neural network (ANN) model for predicting the efficacy of first-line FOLFOX chemotherapy for metastatic colorectal cancer. Methods: A set of FOLFOX chemotherapy data from a group of patients with metastatic colorectal cancer (mCRC) (GSE104645) was downloaded from the GEO database as a training set. According to the FOLFOX protocol, the efficacy was divided into two groups: the chemo-sensitive group (including complete response and partial response) and the chemo-resistant group (including stable disease and progressive disease), including 31 cases in the sensitive group and 23 in the resistant group. Then, chip data (accessible number: GSE69657) from Fujian Medical University Union Hospital were chosen as a test set. A total of 30 patients were enrolled in the study, including 13 in the sensitive group and 17 in the resistant group. The batch effect correction was performed on the expression values of the two sets of matrices using the R 3.5.1 software Combat package. The gene expression difference of sensitive and resistant group in GSE104645 was analyzed by the GEO2R platform. P<0.05 and the absolute value of log(2)FC>0.33 (FC abbreviation of fold change) were used as the threshold value to screen the drug resistance and sensitive genes of the FOLFOX regimen. An ANN was constructed using the multi-layer perceptron (MLP) to perform the FOLFOX regimen on the GSE104645 dataset. The GSE69657 expression matrix and clinical efficacy parameters were then used for retrospective verification. Receiver operating characteristic(ROC) curves were used to evaluate the test results and predictive power. Results: A total of 2, 076 differentially expressed genes in GSE104645 were selected, of which 822 genes were up-regulated and 1, 254 genes were down-regulated in the chemo-resistance group. The down-regulated genes were sensitive genes. GO analysis of the biological processes in which the differentially expressed genes were involved, revealed that they were mainly involved in the regulation of substance metabolism. A total of 39 genes were included in the final model construction. This was a neural network model with two hidden layers. The accuracy of predicting training samples and test samples was 75.7% and 76.5%, respectively, and the area under the ROC curve was 0.875. The chip data set of our department (GSE69657) was set as the test set, and the area under the ROC curve was 0.778. Conclusions: In this study, an artificial neural network model is successfully constructed to predict the efficacy of first-line FOLFOX regimen for metastatic colorectal cancer based on the microarray, and an independent external verification is also conducted. The model has good stability and well prediction efficiency. Besides, the results of this study suggest that the gene functions related to oxaliplatin resistance are mainly enriched in the regulation process of substance metabolism. 目的: 构建预测FOLFOX方案(奥沙利铂+亚叶酸钙+氟尿嘧啶)一线治疗转移性结直肠癌(mCRC)疗效的人工神经网络模型。 方法: 从美国国家生物信息中心的基因表达汇编(GEO)数据库获取1组FOLFOX方案一线治疗mCRC的数据(GSE104645)作为训练集,其中FOLFOX方案疗效敏感组(完全缓解和部分缓解患者)31例,耐药组(疾病稳定和疾病进展患者)23例。将训练集样本按7∶3分为内部训练样本和内部测试样本。以福建医科大学附属协和医院结直肠外科采用FOLFOX方案一线治疗的30例mCRC患者的芯片数据集(GSE69657)作为外部验证样本,其中敏感组13例,耐药组17例。运用R 3.5.1软件Combat包对两套矩阵的表达值进行批间差校正。运用GEO2R平台对GSE104645中敏感组和耐药组的基因表达进行差异分析,以P<0.05且|log(2)FC|>0.33(FC为差异倍数)为阈值,筛选FOLFOX方案的耐药基因和敏感基因。采用多层感知器方法对GSE104645数据集进行FOLFOX方案疗效的人工神经网络模型构建。然后,以外部验证样本进行回代验证。采用受试者工作特征(ROC)曲线对所建模型的预测能力进行评价。 结果: 基于GSE104645数据集,共筛选出2 076个差异基因,其中822个基因在耐药组上调,1 254个基因下调,下调基因为敏感基因。基因本体论(GO)分析显示,差异基因主要富集在物质代谢的调控过程中。所构建的人工神经网络模型共纳入39个基因,包含2个隐藏层。其在训练集中预测训练样本和测试样本的准确度分别为75.7%和76.5%,ROC曲线下面积为0.875。回代验证显示,外部验证样本的ROC曲线下面积为0.778。 结论: 基于芯片数据成功建立了人工神经网络预测模型,模型稳定性好,预测FOLFOX方案一线治疗mCRC疗效的效能强。与奥沙利铂耐药相关的基因功能主要富集在物质代谢的调控过程中。.
引用
- Lin SM, Wang XJ, Huang SH, et al. [Construction of artificial neural network model for predicting the efficacy of first-line FOLFOX chemotherapy for metastatic colorectal cancer]. Zhonghua Zhong Liu Za Zhi. 2021. PMID: 33601485. doi:10.3760/cma.j.cn112152-20200419-00355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。